Medical News / From ASH 2021 - Novel Lentiviral Vectors Achieve Efficient Correction of Sickling Phenotype

Investigators aimed to improve lentiviral vectors to boost therapeutic β-like globin levels without increasing the mutagenic vector load in hematopoietic stem/progenitor cells. Investigators from Europe created a lentiviral vector able to concomitantly silence the βS-globin and express β-Alanine synthase (βAS), achieving clinically relevant levels of therapeutic hemoglobin (Hb) and efficient correction of the sickling phenotype. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell ... read more
Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored ... read more
While patients with sickle cell disease (SCD) are at an increased risk of hospitalization with a ... read more
High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity ... read more